Finance

Lists
Why is CAMP up 3,37%?
Dive Deeper
CAMP:NASDAQ
CAMP4 Therapeutics Corp
USD 3,99
+3,37%
(+0,13) 1D
17 Nov., 15:43:03 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CAMP...
Open
USD 3,90
High
USD 4,09
Low
USD 3,87
Mkt. cap
250,39 m
Avg. vol.
172,55 k
Volume
155,25 k
52-wk high
USD 7,75
52-wk low
USD 2,90
EPS
-USD 2,01
Shares outstanding
62,75 m
No. of employees
48
Open
USD 3,90
High
USD 4,09
Low
USD 3,87
Mkt. cap
250,39 m
Avg. vol.
172,55 k
Volume
155,25 k
52-wk high
USD 7,75
52-wk low
USD 2,90
EPS
-USD 2,01
Shares outstanding
62,75 m
No. of employees
48
News stories
From web sources and news partners
About CAMP4 Therapeutics Corp
CEO-
Employees48
Founded2015
Headquarters-
SectorHealth Care
Industry-
Analyst ratings
Based on 8 analysts giving stock ratings to CAMP in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for CAMP in the last 3 months.
Highest
Current USD 3,99
USD 15,00 (+275,94%)
Average
USD 9,00 (+125,56%)
Lowest
USD 6,00 (+50,38%)
Analyst
Recommendation
Action
Price target
Projected
Date
Anupam Rama
J.P. Morgan
Buy
Maintained
USD 9,00
+125,6%
11/11/2026
Yun Zhong
Wedbush
Buy
Maintained
USD 8,00
+100,5%
11/06/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Maintained
USD 7,00
+75,4%
11/05/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
USD 15,00
+275,9%
11/06/2026
Tiago Fauth
Raymond James
Buy
Initiated
USD 10,00
+150,6%
10/23/2026
Joseph Stringer
Needham
Buy
Initiated
USD 8,00
+100,5%
10/15/2026
Keay Nakae
Chardan Capital
Buy
Reiterated
USD 6,00
+50,4%
09/29/2026
Myles Minter
William Blair
Buy
Reiterated
-
-
09/29/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
USD 7,00
+75,4%
04/14/2026
Mani Foroohar
Leerink Partners
Buy
Maintained
USD 9,00
+125,6%
04/02/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Des. 2025
Mrt. 2026
Jun. 2026
Sep. 2026
Revenue
348,00 k
1,29 m
1,78 m
1,90 m
Cost of goods sold
8,36 m
10,16 m
10,82 m
11,43 m
Cost of revenue
8,36 m
10,16 m
10,82 m
11,43 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4,77 m
4,20 m
4,34 m
4,49 m
Operating expense
4,77 m
4,20 m
4,34 m
4,49 m
Total operating expenses
13,12 m
14,36 m
15,16 m
15,93 m
Operating income
-12,78 m
-13,07 m
-13,38 m
-14,03 m
Other non operating income
-28,22 m
-6,17 m
-20,96 m
-15,91 m
EBT including unusual items
-40,28 m
-18,33 m
-33,53 m
-28,96 m
EBT excluding unusual items
-40,28 m
-18,33 m
-33,53 m
-28,96 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-40,28 m
-18,33 m
-33,53 m
-28,96 m
Net profit margin
-11 575,86%
-1 416,62%
-1 884,77%
-1 524,80%
Earnings per share
-0,23
-0,21
-0,22
-0,17
Interest and investment income
716,00 k
910,00 k
807,00 k
984,00 k
Interest expense
-
-
-
-
Net interest expenses
716,00 k
910,00 k
807,00 k
984,00 k
Depreciation and amortization charges
-
-
-
-
EBITDA
-12,40 m
-12,55 m
-12,86 m
-13,51 m
Gain or loss from assets sale
191,00 k
-
-
98,00 k
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google-programme